To test this hypothesis, we first verified whether HOXA11-AS expression could affect ROS levels in glioma, and found that of HOXA11-AS knockdown did not affect intracellular ROS levels in U87 and LN229 cells (Fig. S17E). Here, HOXA11 is linked to central nervous system cancer.